AlzeCure Pharma AB (publ) (ALZCUR.ST)
SEK 2.3
(-5.74%)
SEK 2.3
(-5.74%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 32 Million SEK | -54.82% |
| 2022 | 70.83 Million SEK | 55.18% |
| 2021 | 45.64 Million SEK | -61.26% |
| 2020 | 117.82 Million SEK | -36.91% |
| 2019 | 186.75 Million SEK | -21.46% |
| 2018 | 237.78 Million SEK | 324.83% |
| 2017 | 55.97 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 47.25 Million SEK | 108.29% |
| 2024 Q1 | 22.68 Million SEK | -29.1% |
| 2023 Q4 | 32 Million SEK | -20.78% |
| 2023 Q1 | 57.97 Million SEK | -18.16% |
| 2023 FY | 32 Million SEK | -54.82% |
| 2023 Q2 | 48.11 Million SEK | -17.0% |
| 2023 Q3 | 40.39 Million SEK | -16.05% |
| 2022 Q4 | 70.83 Million SEK | 74.96% |
| 2022 Q3 | 40.48 Million SEK | -26.79% |
| 2022 Q2 | 55.3 Million SEK | -26.81% |
| 2022 Q1 | 75.56 Million SEK | 65.53% |
| 2022 FY | 70.83 Million SEK | 55.18% |
| 2021 Q4 | 45.64 Million SEK | -33.17% |
| 2021 FY | 45.64 Million SEK | -61.26% |
| 2021 Q2 | 82.03 Million SEK | -17.2% |
| 2021 Q3 | 68.29 Million SEK | -16.74% |
| 2021 Q1 | 99.06 Million SEK | -15.92% |
| 2020 FY | 117.82 Million SEK | -36.91% |
| 2020 Q4 | 117.82 Million SEK | -14.82% |
| 2020 Q1 | 176.4 Million SEK | -5.54% |
| 2020 Q2 | 160.05 Million SEK | -9.27% |
| 2020 Q3 | 138.33 Million SEK | -13.57% |
| 2019 Q4 | 186.75 Million SEK | -7.36% |
| 2019 Q3 | 201.59 Million SEK | -6.42% |
| 2019 Q2 | 215.41 Million SEK | -4.63% |
| 2019 FY | 186.75 Million SEK | -21.46% |
| 2019 Q1 | 225.87 Million SEK | -5.01% |
| 2018 Q3 | 66.96 Million SEK | 0.0% |
| 2018 FY | 237.78 Million SEK | 324.83% |
| 2018 Q4 | 237.78 Million SEK | 255.06% |
| 2018 Q1 | - SEK | -100.0% |
| 2017 FY | 55.97 Million SEK | 0.0% |
| 2017 Q4 | 55.97 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AcuCort AB | 58.5 Million SEK | 45.304% |
| BioGaia AB (publ) | 2.33 Billion SEK | 98.628% |
| Enzymatica AB (publ) | 125.91 Million SEK | 74.584% |
| Enorama Pharma AB (publ) | 34.38 Million SEK | 6.933% |
| Gabather AB (publ) | 2.93 Million SEK | -989.581% |
| Klaria Pharma Holding AB (publ.) | 73.12 Million SEK | 56.235% |
| Moberg Pharma AB (publ) | 634.73 Million SEK | 94.958% |
| Nanexa AB (publ) | 132.25 Million SEK | 75.804% |
| Newbury Pharmaceuticals AB (publ) | 90.87 Million SEK | 64.784% |
| ODI Pharma AB | 12.27 Million SEK | -160.701% |
| Orexo AB (publ) | 786.6 Million SEK | 95.932% |
| Probi AB (publ) | 1.55 Billion SEK | 97.936% |
| Swedencare AB (publ) | 9.52 Billion SEK | 99.664% |
| Swedish Orphan Biovitrum AB (publ) | 74.02 Billion SEK | 99.957% |
| Toleranzia AB | 160.42 Million SEK | 80.053% |
| Vivesto AB | 355.87 Million SEK | 91.008% |